From the immunoprofile of NOX4 in normal, dysplastic, and malignant urothelial cells, NOX4 might be involved in an early stage of urothelial carcinogenesis and be a potential new molecular target for bladder cancer therapy. The gene discussed is NOX4; the disease is urinary bladder cancer.